RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PDS Biotechnology Stock

PDS Biotechnology P/E 2025

PDS Biotechnology P/E

-1.16

Ticker

PDSB

ISIN

US70465T1079

WKN

A2PF3F

As of Jul 25, 2025, PDS Biotechnology's P/E ratio was -1.16, a -26.58% change from the -1.58 P/E ratio recorded in the previous year.

The PDS Biotechnology P/E history

PDS Biotechnology Aktienanalyse

What does PDS Biotechnology do?

PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering PDS Biotechnology's P/E Ratio

The Price to Earnings (P/E) Ratio of PDS Biotechnology is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing PDS Biotechnology's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of PDS Biotechnology is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in PDS Biotechnology’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about PDS Biotechnology stock

What is the price-to-earnings ratio of PDS Biotechnology?

The price-earnings ratio of PDS Biotechnology is currently -1.16.

How has the price-earnings ratio of PDS Biotechnology changed compared to last year?

The price-to-earnings ratio of PDS Biotechnology has increased by -26.58% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of PDS Biotechnology high compared to other companies?

Yes, the price-to-earnings ratio of PDS Biotechnology is high compared to other companies.

How does an increase in the price-earnings ratio of PDS Biotechnology affect the company?

An increase in the price-earnings ratio of PDS Biotechnology would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of PDS Biotechnology affect the company?

A decrease in the price-earnings ratio of PDS Biotechnology would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of PDS Biotechnology?

Some factors that influence the price-earnings ratio of PDS Biotechnology are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does PDS Biotechnology pay?

Over the past 12 months, PDS Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PDS Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of PDS Biotechnology?

The current dividend yield of PDS Biotechnology is .

When does PDS Biotechnology pay dividends?

PDS Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PDS Biotechnology?

PDS Biotechnology paid dividends every year for the past 0 years.

What is the dividend of PDS Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PDS Biotechnology located?

PDS Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von PDS Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PDS Biotechnology from 7/25/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/25/2025.

When did PDS Biotechnology pay the last dividend?

The last dividend was paid out on 7/25/2025.

What was the dividend of PDS Biotechnology in the year 2024?

In the year 2024, PDS Biotechnology distributed 0 USD as dividends.

In which currency does PDS Biotechnology pay out the dividend?

The dividends of PDS Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The PDS Biotechnology stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von PDS Biotechnology

Our stock analysis for PDS Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PDS Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.